Abstract:Background Immune checkpoint blockade targeting the adaptive immune system has revolutionized the treatment of cancer. Despite impressive clinical benefits observed, patient subgroups remain non-responsive underscoring the necessity for combinational therapies harnessing additional immune cells. Natural killer (NK) cells are emerging tools for cancer therapy. However, only subpopulations of NK cells that are differentially controlled by inhibitory receptors exert reactivity against particular cancer types. How to leverage the complete anti-tumor potential of all NK cell subsets without favoring the emergence of NK cell-resistant tumor cells remains unresolved. Methods We performed a genome-wide CRISPR/Cas9 knockout resistance screen in melanoma cells in co-cultures with human primary NK cells. We comprehensively evaluated factors regulating tumor resistance and susceptibility by focusing on NK cell subsets in an allogenic setting. Moreover, we tested therapeutic blocking antibodies currently used in clinical trials. Results Melanoma cells deficient in antigen-presenting or the IFNγ-signaling pathways were depleted in remaining NK cell-co-cultured melanoma cells and displayed enhanced sensitivity to NK cells. Treatment with IFNγ induced potent resistance of melanoma cells to resting, IL-2-cultured and ADCC-activated NK cells that depended on B2M required for the expression of both classical and non-classical MHC-I. IFNγ-induced expression of HLA-E mediated the resistance of melanoma cells to the NKG2A + KIR − and partially to the NKG2A + KIR + NK cell subset. The expression of classical MHC-I by itself was sufficient for the inhibition of the NKG2A − KIR + , but not the NKG2A + KIR + NK cell subset. Treatment of NK cells with monalizumab, an NKG2A blocking mAb, enhanced the reactivity of a corresponding subset of NK cells. The combination of monalizumab with lirilumab, blocking KIR2 receptors, together with DX9, blocking KIR3DL1, was required to restore cytotoxicity of all NK cell subsets against IFNγ-induced resistant tumor cells in melanoma and tumors of different origins. Conclusion Our data reveal that in the context of NK cells, IFNγ induces the resistance of tumor cells by the upregulation of classical and non-classical MHC-I. Moreover, we reveal insights into NK cell subset reactivity and propose a therapeutic strategy involving combinational monalizumab/lirilumab/DX9 treatment to fully restore the antitumor response across NK cell subsets.

Intermediate monocytes induced by IFN-γ inhibit cancer metastasis by promoting NK cell activation through FOXO1 and interleukin-27

Activated Mouse CD4+Foxp3- T Cells Facilitate Melanoma Metastasis Via Qa-1-dependent Suppression of NK Cell Cytotoxicity (127.17)

Concomitant Type I IFN and M-CSF Signaling Reprograms Monocyte Differentiation and Drives Pro-Tumoral Arginase Production

A Monocyte-Orchestrated IFN-I-to-IL-4 Cytokine Axis Instigates Protumoral Macrophages and Thwarts Poly(I:C) Therapy.

IFN-γ-dependent NK Cell Activation is Essential to Metastasis Suppression by Engineered Salmonella.

Identification of Resting and Type I Ifn-Activated Human Nk Cell Mirnomes Reveals Microrna-378 and Microrna-30e As Negative Regulators of Nk Cell Cytotoxicity

Primary Tumors Limit Metastasis Formation through Induction of IL15-Mediated Cross-Talk between Patrolling Monocytes and NK Cells

Tumor-Induced Suppression of Interferon-Gamma Production and Enhancement of Interleukin-10 Production by Natural Killer (nk) Cells: Paralleled to Cd4(+) T Cells

Interferon-gamma signaling promotes melanoma progression and metastasis

Interleukin-10 overexpression in 4T1 cells: A gateway to suppressing mammary carcinoma growth

IFNγ mediates the resistance of tumor cells to distinct NK cell subsets

Use of optimized single-cell RNA flow cytometry protocol identifies monocytes as main producers of type I interferon in mouse syngeneic tumors

Inducible CCR2+ nonclassical monocytes mediate the regression of cancer metastasis

Host-derived Interleukin 1α induces an immunosuppressive tumor microenvironment via regulating monocyte-to-macrophage differentiation

NK cells promote cancer immunoediting through tumor-intrinsic loss of interferon-stimulated gene expression

Type I Interferons Exert Anti-Tumor Effect Via Reversing Immunosuppression Mediated by Mesenchymal Stromal Cells.

Opposing Effect of IFNγ and IFNα on Expression of NKG2 Receptors: Negative Regulation of IFNγ on NK Cells

IFNγ-dependent remodelling of the myeloid landscape underlies control of IFNγ-insensitive tumours

IFN-γ Induces Epithelial-to-mesenchymal Transition of Cancer Cells Via an Unique Microrna Processing

Modulation of Gene Expression in MHCC97 Cells by Interferon Alpha

Inhibition of Tumor Angiogenesis by Interferon-Γ by Suppression of Tumor-Associated Macrophage Differentiation.